These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 10627280)

  • 1. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells.
    Li C; Hampson IN; Hampson L; Kumar P; Bernabeu C; Kumar S
    FASEB J; 2000 Jan; 14(1):55-64. PubMed ID: 10627280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells.
    Warrington K; Hillarby MC; Li C; Letarte M; Kumar S
    Anticancer Res; 2005; 25(3B):1851-64. PubMed ID: 16158917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD105 prevents apoptosis in hypoxic endothelial cells.
    Li C; Issa R; Kumar P; Hampson IN; Lopez-Novoa JM; Bernabeu C; Kumar S
    J Cell Sci; 2003 Jul; 116(Pt 13):2677-85. PubMed ID: 12746487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoglin is overexpressed after arterial injury and is required for transforming growth factor-beta-induced inhibition of smooth muscle cell migration.
    Ma X; Labinaz M; Goldstein J; Miller H; Keon WJ; Letarte M; O'Brien E
    Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2546-52. PubMed ID: 11116051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development.
    Arthur HM; Ure J; Smith AJ; Renforth G; Wilson DI; Torsney E; Charlton R; Parums DV; Jowett T; Marchuk DA; Burn J; Diamond AG
    Dev Biol; 2000 Jan; 217(1):42-53. PubMed ID: 10625534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF alpha down-regulates CD105 expression in vascular endothelial cells: a comparative study with TGF beta 1.
    Li C; Guo B; Ding S; Rius C; Langa C; Kumar P; Bernabeu C; Kumar S
    Anticancer Res; 2003; 23(2B):1189-96. PubMed ID: 12820370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105.
    Li C; Guo B; Bernabeu C; Kumar S
    Microsc Res Tech; 2001 Feb; 52(4):437-49. PubMed ID: 11170303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies.
    Fonsatti E; Del Vecchio L; Altomonte M; Sigalotti L; Nicotra MR; Coral S; Natali PG; Maio M
    J Cell Physiol; 2001 Jul; 188(1):1-7. PubMed ID: 11382917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective angiogenesis in mice lacking endoglin.
    Li DY; Sorensen LK; Brooke BS; Urness LD; Davis EC; Taylor DG; Boak BB; Wendel DP
    Science; 1999 May; 284(5419):1534-7. PubMed ID: 10348742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD105 inhibits transforming growth factor-beta-Smad3 signalling.
    Guo B; Slevin M; Li C; Parameshwar S; Liu D; Kumar P; Bernabeu C; Kumar S
    Anticancer Res; 2004; 24(3a):1337-45. PubMed ID: 15274293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD105 is important for angiogenesis: evidence and potential applications.
    Duff SE; Li C; Garland JM; Kumar S
    FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
    She X; Matsuno F; Harada N; Tsai H; Seon BK
    Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
    Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
    Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury.
    Botella LM; Sánchez-Elsner T; Sanz-Rodriguez F; Kojima S; Shimada J; Guerrero-Esteo M; Cooreman MP; Ratziu V; Langa C; Vary CP; Ramirez JR; Friedman S; Bernabéu C
    Blood; 2002 Dec; 100(12):4001-10. PubMed ID: 12433697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II via activation of type 1 receptor upregulates expression of endoglin in human coronary artery endothelial cells.
    Li D; Chen H; Mehta JL
    Hypertension; 2001 Nov; 38(5):1062-7. PubMed ID: 11711498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma.
    Altomonte M; Montagner R; Fonsatti E; Colizzi F; Cattarossi I; Brasoveanu LI; Nicotra MR; Cattelan A; Natali PG; Maio M
    Br J Cancer; 1996 Nov; 74(10):1586-91. PubMed ID: 8932339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of protein kinase Calpha prevents endothelial cell migration and vascular tube formation in vitro and myocardial neovascularization in vivo.
    Wang A; Nomura M; Patan S; Ware JA
    Circ Res; 2002 Mar; 90(5):609-16. PubMed ID: 11909826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoglin (CD105): a target for anti-angiogenetic cancer therapy.
    Fonsatti E; Altomonte M; Arslan P; Maio M
    Curr Drug Targets; 2003 May; 4(4):291-6. PubMed ID: 12699349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.
    Nolan-Stevaux O; Zhong W; Culp S; Shaffer K; Hoover J; Wickramasinghe D; Ruefli-Brasse A
    PLoS One; 2012; 7(12):e50920. PubMed ID: 23300529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
    Xiong YQ; Sun HC; Zhang W; Zhu XD; Zhuang PY; Zhang JB; Wang L; Wu WZ; Qin LX; Tang ZY
    Clin Cancer Res; 2009 Aug; 15(15):4838-46. PubMed ID: 19638466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.